BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10682270)

  • 1. Immunohistochemical detection of lactoferrin in human astrocytomas and multiforme glioblastomas.
    Tuccari G; Giuffrè G; Crisafulli C; Barresi G
    Eur J Histochem; 1999; 43(4):317-22. PubMed ID: 10682270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras p21 expression in brain tumors: elevated expression in malignant astrocytomas and glioblastomas multiforme.
    Arvanitis D; Malliri A; Antoniou D; Linardopoulos S; Field JK; Spandidos DA
    In Vivo; 1991; 5(4):317-21. PubMed ID: 1667267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annexin II marks astrocytic brain tumors of high histologic grade.
    Roseman BJ; Bollen A; Hsu J; Lamborn K; Israel MA
    Oncol Res; 1994; 6(12):561-7. PubMed ID: 7787249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
    Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
    Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleolar organizer regions (AgNORs) in astrocytic tumors.
    Pedal WP; Warzok RW; Hufnagl P; Roth K
    Zentralbl Pathol; 1994 Mar; 140(1):89-94. PubMed ID: 7515679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical localization of basic fibroblast growth factor in astrocytomas.
    Zagzag D; Miller DC; Sato Y; Rifkin DB; Burstein DE
    Cancer Res; 1990 Nov; 50(22):7393-8. PubMed ID: 2171762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Fas/APO-1 during the progression of astrocytomas.
    Tachibana O; Nakazawa H; Lampe J; Watanabe K; Kleihues P; Ohgaki H
    Cancer Res; 1995 Dec; 55(23):5528-30. PubMed ID: 7585627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of Hsp-27 in astrocytic brain tumors: an immunohistochemical study.
    Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Varakis I
    Anticancer Res; 1997; 17(4A):2677-82. PubMed ID: 9252700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of glial fibrillary acidic protein and protein S-100 in cerebral astrocytic gliomas of varying degrees of malignancy (immunohistochemical study)].
    Korshunov AG; Sycheva RV
    Arkh Patol; 1995; 57(4):30-8. PubMed ID: 8526753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis.
    Mikkelsen T; Yan PS; Ho KL; Sameni M; Sloane BF; Rosenblum ML
    J Neurosurg; 1995 Aug; 83(2):285-90. PubMed ID: 7542317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor (VEGF) receptor neuropilin-1's distribution in astrocytic tumors.
    Broholm H; Laursen H
    APMIS; 2004; 112(4-5):257-63. PubMed ID: 15233640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
    Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
    Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults.
    Matsumoto T; Fujii T; Yabe M; Oka K; Hoshi T; Sato K
    Histopathology; 1998 Nov; 33(5):446-52. PubMed ID: 9839169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic studies on low- and high-grade human brain astrocytomas.
    Odreman F; Vindigni M; Gonzales ML; Niccolini B; Candiano G; Zanotti B; Skrap M; Pizzolitto S; Stanta G; Vindigni A
    J Proteome Res; 2005; 4(3):698-708. PubMed ID: 15952716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.
    Reilly KM; Loisel DA; Bronson RT; McLaughlin ME; Jacks T
    Nat Genet; 2000 Sep; 26(1):109-13. PubMed ID: 10973261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microtubule-associated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas.
    Wharton SB; Chan KK; Whittle IR
    J Clin Neurosci; 2002 Mar; 9(2):165-9. PubMed ID: 11922706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of the bromodeoxyuridine labeling index of astrocytic tumors between primary and recurrent lesions.
    Tamura M; Ono N; Zama A; Kurihara H
    Noshuyo Byori; 1994; 11(2):173-6. PubMed ID: 7894621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of protein conformation in human benign and malignant astrocytomas by reflectance Fourier transform infrared microspectroscopy.
    Lee LS; Chi CW; Liu HC; Cheng CL; Li MJ; Lin SY
    Oncol Res; 1998; 10(1):23-7. PubMed ID: 9613454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological study of cellular proliferation and invasion in gliomatosis cerebri: important role of neural cell adhesion molecule L1 in tumour invasion.
    Suzuki T; Izumoto S; Fujimoto Y; Maruno M; Ito Y; Yoshimine T
    J Clin Pathol; 2005 Feb; 58(2):166-71. PubMed ID: 15677537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Labeling and quantitative analysis of six lectin receptors of intracranial gliomas.
    Yang S; Liu Z; Zhu Y; Chen X
    Chin Med J (Engl); 1995 Jan; 108(1):37-43. PubMed ID: 7712837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.